ABSK011's efficacy and safety performance are revolutionary ...

ABSK011's efficacy and safety performance are revolutionary and exciting, which also shows its significant potential to break the deadlock in second-line liver cancer treatment and reach advanced patients. Despite the variety of PD-1/PD-L1 antibody drugs, small-molecule inhibitors may be insufficient to improve antibody immunotherapy. This indicates that Hwayu Pharmaceutical may usher in a revaluation of its market value.